Literature DB >> 7493064

Increased tumor oxygenation and radiation sensitivity in two rat tumors by a hemoglobin-based, oxygen-carrying preparation.

M F Robinson1, N P Dupuis, T Kusumoto, F Liu, K Menon, B A Teicher.   

Abstract

The rat 13762 mammary carcinoma and the rat 9L gliosarcoma were grown subcutaneously in a hind limb of female, Fisher 344 rats. The oxygen content of the tumors was determined using an Eppendorf pO2 histograph. Fifty-to-sixty oxygen measurements were made per tumor and there were 8-to-10 animals per group. The percent of pO2 readings < or = 5 mmHg in the mammary carcinoma was 49%, this was decreased to 34% by administration of the hemoglobin preparation (8 ml/kg) and further decreased to 29% when carbogen (95% O2/5% CO2) breathing was added to administration of the hemoglobin preparation. The percent of pO2 readings < or = 5 mmHg in the gliosarcoma was 49%, this was decreased to 24% by administration of the hemoglobin preparation and further decreased to 0% when carbogen breathing was added to administration of the hemoglobin preparation. Therapeutic response was assessed over a single-dose range of radiation therapy (10, 20 and 30 Gray). The dose modifying factor produced by the hemoglobin preparation/air was 1.6 and by the hemoglobin preparation/carbogen was 2.7 in the rat 13762 mammary carcinoma. The dose modifying factor produced by the hemoglobin preparation/air was 1.9 and by the hemoglobin preparation/carbogen was 2.9 in the rat 9L gliosarcoma. Administration of a hemoglobin-based oxygen carrier reduced tumor hypoxia and increased tumor response to radiation therapy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7493064     DOI: 10.3109/10731199509117959

Source DB:  PubMed          Journal:  Artif Cells Blood Substit Immobil Biotechnol        ISSN: 1073-1199


  3 in total

1.  Hypoxia and radiation therapy: past history, ongoing research, and future promise.

Authors:  Sara Rockwell; Iwona T Dobrucki; Eugene Y Kim; S Tucker Marrison; Van Thuc Vu
Journal:  Curr Mol Med       Date:  2009-05       Impact factor: 2.222

2.  Glutaraldehyde-polymerized bovine hemoglobin and phosphodiesterase-5 inhibition.

Authors:  Robert W Gotshall; Karyn L Hamilton; Benjamin Foreman; Martha C Tissot van Patot; David C Irwin
Journal:  Crit Care Med       Date:  2009-06       Impact factor: 7.598

Review 3.  Detection of Hypoxia in Cancer Models: Significance, Challenges, and Advances.

Authors:  Inês Godet; Steven Doctorman; Fan Wu; Daniele M Gilkes
Journal:  Cells       Date:  2022-02-16       Impact factor: 6.600

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.